COMPANY DIRECTORY

• AcouSort AB (Exosome Seperation Tech & Diagnostics)

• √ AcouSort AB is a Swedish company that is pioneering acoustofluidic technology, as well as working on exosome-based diagnostics. In August 2022, the European Innovation Council (EIC) awarded AcouSort and its project partners SEK $26 million (approximately $2.5 million USD) to develop an acoustofluidic thin-film actuated chip for exosome separation from blood. Roughly half of that will go directly to AcouSort, while the rest of the funding is being provided to AcouSort’s partners Lund University, DTU, and Day One.

• Aegle Therapeutics      (Clinical Stage Biotech)

• √ Aegle Therapeutics Corp. is a first in class, Phase 1/2a ready, biotechnology company isolating extracellular vesicles (“EVs”) from allogeneic bone marrow derived mesenchymal stem cells (BM-MSCs) to treat severe dermatological conditions, including burns and epidermolysis bullosa, a rare pediatric connective tissue disorder, and to prevent scarring. Aegle’s isolation process allows for the production of therapeutic-grade extracellular vesicles from bone marrow derived MSCs. In April of 2018, the U.S. Food and Drug Administration (FDA) cleared the company’s first Investigational New Drug (IND) application to begin clinical trials in burn patients.

• 01/11/2024 Aegle Therapeutics Corp. Announces Positive Data for the First Patient in a Phase 1/2a Clinical Trial Dosed With AGLE-102™, a Novel Extracellular Vesicle Therapy

  • [2022] Schulman CI, Namias N, Pizano L, Rodriguez-Menocal L, Aickara D, Guzman W, Candanedo A, Maranda E, Beirn A, McBride JD, Badiavas EV. The effect of mesenchymal stem cells improves the healing of burn wounds: a phase 1 dose-escalation clinical trial. Scars Burn Heal. 2022 Jun 28;8:20595131211070783.

    [2021] McBride et al. Proteomic analysis of bone marrow-derived mesenchymal stem cell extracellular vesicles from healthy donors: implications for proliferation, angiogenesis, Wnt signaling and the basement membrane. Stem Cell Res Ther 12, 328 (2021).

• AgeX Therapeutics

• AgeX”; NYSE American: AGE

• AgeX Therapeutics is focused on the development and commercialization of novel therapeutics targeting human aging. We are building upon the foundation of our proprietary technologies such as PureStem® and induced Tissue Regeneration (iTR™) to develop innovative medicines designed to address some of the largest unsolved problems in aging. Through PureStem® we have the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging with a high unmet medical need. iTR™ is our revolutionary longevity platform aiming to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body.

  
  

• Aethlon Medical, Inc.      (Clinical Stage Biotech)

• √ Aethlon Medical (NASDAQ: AEMD) is an American company focused on addressing unmet needs in global health and biodefense. It initiated its tumor-derived exosome research at a time when the medical community believed exosomes were cellular debris. Today, a therapeutic to address tumor-derived exosomes represents a significant unmet need in cancer care. Aethlon has demonstrated that the affinity mechanism of the Hemopurifier® can capture tumor-derived exosomes underlying several forms of cancer, including breast, ovarian and metastatic melanoma.
  

• AGC Biologics      (Contract Biological Manufacturing)

• √ AGC Biologics is a global CDMO providing development and manufacturing services for protein-based biologics and advanced therapies.

• In April 2023, AGC Biologics entered a service agreement with Jikei University in Japan. Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug to treat idiopathic pulmonary fibrosis (IPF). Specifically, ACG scientists will focus on identifying the viability of developing a prototype for an exosome-based treatment of IPF derived from bronchial epithelial cells.
  

• AGS Therapeutics      (Drug / Cargo Delivery via Microalgae)

• √ AGS Therapeutics is developing novel biomedicines utilizing extracellular vesicles from microalgae (MEV). This approach provides a safe, targeted, and highly versatile delivery system for therapeutic molecules and vaccines. MEVs can pass through the body’s natural barriers to carry biologics (such as mRNA, siRNA, DNA, peptides, and proteins) to specific tissues, while avoiding premature degradation or inactivation.

• The company is involved with microalgae cell engineering and MEV exo-loading technologies, as well as MEV manufacturing at pre-industrial scale through AGS-M. AGS-M is a sister-company of AGS Therapeutics that is fully dedicated to the development of suitable processes for the bioproduction and purification of MEV, as well as the manufacturing of MEV batches for preclinical and clinical use.

• AMSBIO

• √ AMSBIO is a leading supplier of high purity exosomes using isolation methods including traditional differential and gradient ultracentrifugation, immunoaffinity, size exclusion chromatography as well as precipitation / low speed centrifugation.
  

• Anjarium Biosciences AG      (Genetic Delivery Platform)

• √ Hybridosomes® are nanoparticle shells of about 100 nm. Anjarium Bioscience’s Hybridosome® platform excels in conjunction with such optimized RNA modalities, providing an avenue to employ the potential of exosomes in RNA-based applications such as RNAi, mRNA replacement and gene editing. Coupled with the targeting technology and proprietary manufacturing methods, Anjarium’s Hybridosome® platform is a promising technology to overcome the delivery hurdles today’s most powerful RNA therapeutic candidates face.
  

• AnteAGE      (P4$ / Aesthetics Based Biotech)(See Cellese)

• √ AnteAGE® is the result of decades of clinical research in stem cell biology. Its cornerstone technology of bone marrow stem cells was originally used as a wound treatment for diabetes patients. Diabetic wounds heal very slowly, but we discovered years ago that we could coax bone marrow-derived mesenchymal stem cells (MSC) to heal skin wounds rapidly. These stem cells’ natural function is to respond to emergencies in the body through their communication network of biosignaling molecules called cytokines.

• The AnteAGE Exosome Solution is a highly concentrated exosome treatment solution for topical use in combination with microneedling, radiofrequency, laser, and other ablative treatments. This hybrid exosome cocktail derived both from human bone marrow stem cells and human umbilical cord stem cells strikes the ideal balance between potency and stability, resulting in a powerful, potent, ultra-pure exosome treatment solution unlike any other.

  • AnteAGE: Human Bone Marrow Stem Cells and Human Umbilical Cord Stem Cells  | Frozen | Topical / Injectable / Lyophilized 

    MDX 5 ml 10-12 B Exos

• https://anteage.com/products/exosome-solution
  

• Aruna Bio     (Clinical Stage Biotech)  (Proprietary Human Neural Stem Cells)

• √ ArunA Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body’s anti-inflammatory, self-repair and protective mechanisms to treat neurodegenerative disorders. Its proprietary neural exosomes inherently cross the blood-brain barrier and enable drugs and drug-combinations to naturally target cells and treat patients' neurological disorders.

• Avalon

• Founded in 2016; successfully uplisted to Nasdaq (NASDAQ: ALBT), in December 2018; Headquarters in Freehold, New Jersey; approx. 60 FTEs (including subsidiaries)

• Avalon provides extensive support for researchers involved in the Exosome Technology Ecosystem

• Core Technology Platforms:

  • Clinical Laboratory Services/ Precision Diagnostics

  • KetoAir™ breathalyzer device nanosensor technology

  • QTY protein design platform joint intellectual property with Massachusetts Institute of Technology (MIT)
    

• Biological Dynamics             (Diagnostic)

• √ Biological Dynamics has developed an early diagnostic detection test utlizing AC Electrokinetics (ACE) to isolate exosomes from blood, which studies show can identify pancreatic cancer as early as Stage 1

• BOW Project (Collaborative Research Project)

• BOW brings together a strong and complementary consortium, including 11 partners from 7 European countries (Italy, Spain, Germany, Ireland, Switzerland, Estonia, and Czechia). The main objective of BOW is to create hybrid magnetic nanoparticles with a membrane surface made from an extracellular vesicle.

• The BOW project: Nanomedicine’s game-changer

• EU BOW: Biogenic Organotropic Wetsuits: Hybrid magnetic nanoparticles with membrane surfaces made from extracellular vesicles
  

• Brexogen      (Clinical Stage Biotech) (Parental Cell for Exosome Production)

• √ Headquartered in South Korea, Brexogen is developing cell-free strategies to target incurable diseases using stem cell derived exosomes. In November 2022, the US FDA approved initiation of the company’s Phase 1 clinical trial of ‘BRE-AD01’, its exosome-based therapy for atopic dermatitis. This is the first clinical trial of an exosome therapeutic for atopic dermatitis and the first exosome trial being conducted in the United States by a Korean company.
  

• Capricor Therapeutics      (Multi-Stage Clinical Pipeline)

• √ Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of biological therapeutics for the treatment of rare disorders. Its CAP-2003 product is comprised of exosomes isolated from the company’s proprietary cardiosphere-derived cells (CDCs). It is being developed as a next-generation therapeutic platform in regenerative medicine and as a vehicle to deliver therapies to cells in the human body.
  

• Cellese Regenerative Therapeutics      (P4$ / Bone Marrow Stem & Umbilical Cord Stem Cell derived)

• √ Cellese Regenerative Therapeutics is an exosome-based skincare company, with a division called AnteAGE®. It is dedicated to creating innovative, safe, and effective products in it state of the art laboratory.  

• Rob Knight, Lead Scientist

• Cellese Regenerative Therapeutics, Irvine, California, USA.

• See AnteAge for product listing
  

• Cells for Cells      (Clinical Stage Biotech) (MSC-Derived Exosomes)

• √ Cells for Cells (C4C) is a clinical-stage biotech company that is developing XO-101, the company’s flagship exosome therapy derived from mesenchymal stem cells (MSC). In early 2022, C4C dosed the first-ever patient with an exosome-produced therapy for osteoarthritis. Due to this trial’s promising early results, C4C is forming a spin-off company with its exosome asset in the US and opening a Series A funding round with global investors.

• Dr. Greg Chernoff (Clinical Practice) (Aesthetics)

• Dr. Gregory Chernoff has performed plastic surgery, cosmetic treatments, and reconstructive surgery in California for over 30 years. His experience, skills, and expertise have helped patients reach their aesthetic facial and body rejuvenation goals throughout California and across the country.

• Dr. Chernoff has more first hand clinical experience with exosomes than any other physician in the world.

  Education, Fellowship Training, & Specialized Expertise

  • Medical Degree, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

  • BS, Anatomy, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

  • (707) 544-3232

  • office@chernoffcosmeticsurgery.com
    
    

• Ciloa      (Biotech)

• √ Ciloa is a French biotech company, spin-off from the CNRS and the University of Montpellier, a pioneer in the development of vaccines and exosome-based therapies. Based in Montpellier, it was created in 2011 by Robert MAMOUN and Bernadette TRENTIN. Ciloa has an exclusive patented technology for the in vivo development of recombinant exosomes in therapeutic and preventive applications.

• There is strong evidence that exosomes are potent modulators of immune information in an inhibitory or stimulating manner. In the presence of immunogens, the activated dendritic cells produce exosomes that transmit the immune information to the T cells. Consequently, the exosomes can trigger cellular and/or humoral immune responses that result in tumor regression or protection against pathogens.
  

• Clara Biotech      (Acquired by Innovaprep Oct 2023)

• √ Clara Biotech is focused on providing the tools researchers need to harness the full potential of exosomes, including therapeutic, diagnostic and clinical applications. The company is developing a high-throughput lab tool (ExoSS) that aims to automate exosome prootcols, making its world-class exosome isolation service possible in your own lab at rates up to 100 samples/hour.

• Codiak BioSciences, Inc

• √ Filed for bankruptcy and acquired by Lonza?

• Codiak BioSciences is pioneering exosome research and development to create an entirely new class of medicines, exosome therapeutics. Its proprietary engEx™ technology platform for exosome engineering and manufacturing represents a transformative step in the treatment of disease, enabling the development of therapies for diseases that are currently considered intractable. Using this breakthrough platform, it can produce exosomes that have precise and intentionally chosen properties and make them at industrial quality and scale.
  

• ConvEyXO      (XXX)

• √ ConvEyXO is a Belgian company founded in 2019, aspiring to release therapeutic full potential of engineered exosomes. They are developing unique and scalable technology platforms to make engineered exosomes affordable and available for therapeutics, combining cost-effective manufacturing and precise loading for targeted cargo delivery vehicle.
  

• Creative BioLabs      (XXX)

• Exosome Cargo Loading Services

  √ Exosomes have attracted great interest because they participate in pathophysiological processes and have the obvious intrinsic ability to transport a variety of biomolecules between different tissues, organs and cells. As some studies have emphasized, successful loading of therapeutic drugs, from synthetic oligonucleotides to small molecule compounds to viral vectors, can be achieved. Optimizing the loading technology of exosomes will reduce costs and improve productivity, which is an important factor for exosomes to enter the field of treatment.
  

• Creative Biostructure      (XXX)

• √ Creative Biostructure has successfully developed exosome/microvesicle products derived from several different sources. Its range of products include exosomes isolated from cancer cell lines, exosomes isolated from stem cell lines, exosomes isolated from immune-related cell lines, exosomes isolated from general cell lines, exosomes isolated from body fluids, fluorescent exosomes/microvesicles, and lyophilized microvesicles.
  

• Creative Medical Technology Holdings      (XXX)

• √ Creative Medical Technology Holdings is a commercial stage biotechnology company committed to improving patient lives in the areas of Urology, Neurology and Orthopedics. It has a patent application that covers the use of the company’s AmnioStem product as a production tool for the generation of exosomes to regenerate damaged brain tissue after a stroke.

• Creative Proteomics     (Contract Laboratory Services)

• Creative Proteomics provides a one-stop service for Exosome Analysis aiming to conduct a comprehensive analysis of exosome from a holistic perspective. Our one-stop service can include: 1) Exosome isolation service. We can provide classic ultracentrifugation technology or qEV size exclusion technology with better lipoprotein removal effect; 2) Exosomes identification service. We can provide NTA analysis and / or more accurate TRPS analysis; 3) Qualitative and quantitative analysis of exosomes. We can provide labeled and labeled-free protein quantification methods and complete verification services; 4) Data analysis and bioinformatics analysis.

  • Exosome Proteomcis

  • Exosomes Lipidomics

  • Membrane Proteomics

  • Protein Identification

  • Subcellular Multi-omics

  • Tel: 1-631-275-3058 (USA)

    Fax: 1-631-614-7828

    Email: info@creative-proteomics.com
    

• Direct Biologics      (Bone Marrow)

• Lead Product: ExoFlo

• √ Direct Biologics is a biologics manufacturer of regenerative medical products including exosomes. Its ExoFlo exosomes are isolated from donated human mesenchymal stem cells (MSCs) and purified using proprietary processing. According to the company, the benefit to its exosomes is that they are stem cell-derived and bring a wide array of growth factors to stimulate and modulate many processes within the healing cascade.

• ExoFlo™ is an extracellular signal product isolated from human bone marrow MSCs that contains growth factors and extracellular vesicles including exosomes.  It is an investigational new drug and is available through compassionate access.  The current target indication is COVID-19. 

• Contains: VEGF ReceptorAngiogenesisVEGFVascular Endothelial Growth FactorAngiogenesis & ChemotaxisANG1Angiopoietin 1Angiogenesis and Supports VEGFTIMP‑1Collagenase InhibitorBlocks matrix breakdownTIMP‑2Collagenase InhibitorBlocks matrix breakdownIL‑1BInterleukin 1BCell Proliferation, Differentiation, Modulates InflammationPDGF‑AAPlatelet Derived Growth FactorCell Survival & MSC Proliferation – MitogenicTGFb3Transforming Growth Factor Beta 3Immunology – Modulates InflammationbFGFBasic Fibroblast Growth FactorMitogenic Cell Survival and Tissue RegenerationHGFHepatocyte Growth FactorWound Healing – Tissue Regeneration & Organ Survival
  

• Dynacord      (XXX)

• √ Dynacord partners with local Medical Research Institutions to perform cutting edge research on the regenerative properties of stem cell derived exosomes and their contents. Together with researchers, it is laying a foundation for the development of FDA-approved clinical exosome products. The company’s focus is on MSC-derived exosomes from the human umbilical cord.
  

• EriVan Bio      (XXX)

• √ EriVan Bio is a biotech company that is developing products and services that leverage exosome technology for molecular, cell biology research, and therapeutic applications. EriVan Bio was founded to commercialize Dr. Thomas Schmittgen’s groundbreaking research on miRNA and exosomes, focusing on “noncoding RNAs, extracellular vesicles and cancer, with emphasis on the use of microRNAs as therapeutic or diagnostic agents.” Dr. Schmittgen’s lab won the 2018 University of Florida Big Idea Competition.

• EriVan Bio is located at the Sid Martin Biotechnology Incubator in Alachua, Florida, which is globally known for biotechnological innovation. For research use only - not for human or veterinary use.
  

• Esperite

• ESPERITE group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and precision medicine founded in 2000.  Appears to have ceased business operations. 
  

• EV Therapeutics       (Clinical Stage Biotech)

• √ EV Therapeutics is an exosome-based therapeutics company focusing on developing a novel immune modulator based on its proprietary tumor-derived extracellular vesicles (mTEVs) that enhance immunotherapy efficacy in advanced stage colorectal cancers (CRC) and other solid tumor cancers.
  

• EverZom      (XXX)

• √ Incorporated in September 2019, EverZom is a start-up based in France that is developing a GMP compliant extracellular vesicle manufacturing platform. As a CDMO for EVs,  EVerZom aims to overcome the challenge of producing EVs  at commercial scale with a breakthrough patented production method. This technology was developed in collaboration with the University of Paris and the CNRS. The process consists in applying a turbulence stimulation on cells resulting in a increase of the EV production yield by 100 times with minor impact on cell viability.
  

• ExoCan      (XXX)

• √ ExoCan Healthcare Technologies Pvt Ltd. is a Department of Scientific and Industrial Research (DSIR) oncology company that is developing exosome technologies to aid rapid in cancer diagnosis and drug discovery. It is developing a exosome workflow for liquid biopsy and drug delivery in cancer, as well as advancing exosome-based platforms to support the targeted delivery of drugs via engineered exosomes.
  

• Exocelbio      (XXX)

• √ Headquartered at the Pennsylvania Biotechnology Center in Doylestown, PA, Exocelbio is revolutionizing regenerative aesthetic treatments through nanoparticle technology, dedicating years of research to developing innovative natural products. Its Exovex product is made of purified genuine exosomes that are fully active and intact, delivering the highest level of performance available.
  

• ExoCoBio      (XXX)

• √ Headquartered in Seoul, South Korea, ExoCoBio is focusing on stem cell-derived exosomes, to develop innovative therapeutic as well as cosmetic products. The company is exploring the use of stem cell derived-exosomes to regenerate or activate/de-activate various tissues or cells.
  

• Exogems      (XXX)

• √ Exogems is an early-stage Swiss biotech company founded to exploit microfragmented adipose tissue (MFAT) and large amounts of exosomes arising from a revolutionary platform built around the only in-class medical device registered in regenerative medicine by the FDA, namely Lipogems®. Exogems develops a very promising approach for the treatment of central nervous system tumors as shown with preliminary studies. Additional off the shelf applications will include sepsis and septic shock where enhanced survival in the mouse model was also observed.

• Exogenix     (P4$ / Aesthetics Based Biotech)
  √ At Exogenix, we pride ourselves on our innovative approach to harnessing the power of exosomes for optimal health and wellness. Our mission is to provide you with the highest quality exosome products backed by scientific research and cutting-edge technology. 

  Our approach is rooted in scientific advancements and a deep understanding of exosome biology. We work closely with leading researchers and experts in the field to develop state-of-the-art exosome therapies that deliver exceptional results. By staying at the forefront of exosome research, we ensure that our treatments are based on the latest discoveries and innovations.

  • Umbilical Cord MSC Exosomes. AVAILABLE SIZES

    20 Billion Exosomes 1 ml vial

    40 Billion Exosomes 2 ml Vial

    100 Billion Exosomes 5 ml Vial
    

• Exosomedx      (XXX)

• √ Plasma or serum-derived exosomes as diagnostics for prostrate cancer

• CLIA certified product to conduct advanced clinical testing

• Exosomes are microvesicles that are actively released by all living cells into biofluids and are a rich source of biological information - making them an ideal target for assessing prostate cancer risk.
  

• Exopharm Pty Ltd      (XXX)

• √ Exopharm is an Australian regenerative medicine biopharmaceutical company that is seeking to develop and commercialize exosomes as therapeutic agents – initially a product called Plexaris™ and later a product called Exomeres™. Exopharm’s LEAP Technology also provides a key step in the downstream manufacturing process to isolate and purify exosomes from adult stem cells and other sources. Its LEAP Manufacturing Process has been developed to address the existing limitations in exosome purification processes. It entered into a partnership with RoosterBio in August 2017.
  

• ExoProTher      (XXX)

• √ ExoProTher is a preclinical stage company developing a novel oncology therapy based on delivery of a complex of tumor suppressor factors, including tumor protein p53 (p53), using extracellular vesicles as the delivery vehicle.

• Its novel method of healthy p53 protein delivery into tumor cells is expected to assist in the treatment of more than 60% of human cancers, alone or in combination with other agents.
  

• ExoQure      (P4$ / XXX)

• √ ExoQure stem cells and exosomes are the gold standard of UC-MSCs. The company offers high potency and purity, with stringent GMP FDA quality testing at every step of the process of isolation, expansion, harvest, and cryostorage.

• • 50B Exosomes (HUC-MSC-EXO)

  • 50 Billion Exosomes derived from human Umbilical Cord Wharton's Jelly Mesenchymal Stem/ Stromal Cells (Vialed in 1 ml of Clinical Grade Saline)

• • 100B Exosomes (HUC-MSC-EXO)

  • 100 Billion Exosomes derived from human Umbilical Cord Wharton's Jelly Mesenchymal Stem/ Stromal Cells (Vialed in 1 ml or 5 ml of Clinical Grade Saline)

• 25M Mesenchymal Stem / Stromal Cells (HUC-MSC-EXO)

  • 25 million Mesenchymal Stem / Stromal Cells from human Umbilical Cord Wharton's Jelly

• Exosome Hydrogel

• Ingredients: Saline & WJ-MSC Exosomes 1oz.
  

• Exosis      (XXX)

• ? Exosis is experienced in exploiting exosomes, virus-sized particles that bud off cells, in two platforms: creating anti-viral and anti-bacterial vaccines and creating novel therapeutic approaches to cancer. The company has in-house experts in state-of-the art exosome technology, in molecular and cellular immunology as well as the infrastructure and experience necessary for the testing and development of novel Immunotherapeutics, from the laboratory through to clinical trials.  

• Exosome 20      (XXX)
  

• Exosome Diagnostics      (XXX)

• √ Exosome Diagnostics is commercializing minimally invasive molecular diagnostics in blood and urine to enable doctors to select optimal therapies for cancer and other diseases. To do this, it utilizes exosomes, which are lipid bilayer covered microvesicles shed by solid tumors into body fluids, such as blood and urine. For example, its ExoDx™ Prostate Test is a simple, non-DRE, urine-based, liquid biopsy test used to diagnose and assess the risk of prostate cancer.
  

• Exosome Plus      (XXX)

• √ Exosome Plus is pioneering regenerative biotechnology with its exosome-based pharmaceutical platform (ExoThera™). It is focused on providing an “innovative proprietary regenerative pharmaceutical platform, ExoThera™, for irreversible diseases.”
  

• Exosome Sciences      (XXX)

• ( Website: http://exosomesciences.com. ) re-directos to a phishing site

• Exosome Sciences is working in collaboration with its majority shareholder, Aethlon Medical (Nasdaq:AEMD), to discover exosome-based biomarkers to diagnose and monitor Alzheimer’s disease (AD), Chronic Traumatic Encephalopathy (CTE) and other neurological disorders. It is advancing a TauSome™ biomarker (also referred to as exosomal tau) as the basis for a candidate blood test to diagnose CTE in living individuals.
  

• Exosomics S.p.A.       (Diagnositcs) (A Division of HansaBioMed) 

• See Lonza Pharmaceuticals

• √ Exosomics S.p.A., an Italian start-up company developing exosome-based early-stage cancer screening and molecular diagnostic tests. Exosomics has unique IP related to the isolation and selective enrichment of tumor-originated extracellular vesicles (EVs)/exosomes from complex biofluids. Its mission is to develop and commercialize a new generation of tests for cancer screening and liquid biopsy based on analysis of circulating extracellular vesicles and exosomes. The company offers a wide range of proprietary reagents and kits for cancer screening and liquid biopsy, suitable for research use and clinical diagnostics. It also has a strategic partnership with Lonza, entered into in May 2017.
  

• Exostemtech      (XXX)

• √ Exostemtech is a privately held, ventured-backed company that is developing exosome-based therapeutic systems. Specifically, the company is creating therapeutic systems for tissue repair and regeneration, with a focus on treating liver fibrosis and osteoarthritis (OA). EST-P-EXO1 is its experimental treatment based on exosomes extracted from human stem cells that is an osteoarthritis treatment candidate. The company is also developing cosmeceutical products using stem cell-derived exosomes. Exostemtech has secured patents for stem cell-derived exosomes, as well as exosome application technology. It is headquartered in South Korea.
  

• ExSURE      (XXX)

• √ ExSURE is an R&D-based startup that is developing exosome-based cancer therapeutics, including an exosome-based chemotherapeutic drug-delivery platform that can facilitate precise and guided delivery of anti-cancer drugs into tumor cells and relapse-causing cells (cancer stem cells). Currently, it is working with a breast cancer model. The company has filed a provisional patent for the formulation it is using to develop bioengineered, drug-loaded targeted exosomes and the methodology behind it. ExSURE also provides outsourcing services that include cell-culture-based assays, exosome-based experimentations, and cancer stem cell-based assays.
  

• Evolutionary Biologics      (P4$ / XXX)    (Placenta & Umbilical)

• EXO: Wharton’s Jelly MSC-derived exosome  | Frozen | Topical / Injectable / Lyophilized 

  • MDX 5 ml 10-12 B Exos

• √ Evolutionary Biologics manufactures EXO Series, an allogeneic Wharton’s Jelly MSC-derived exosome product. EXO Series is manufactured using the company’s proprietary isolation and purification technologies. It is produced at the company’s cGMP compliant FDA Certified labs using clean rooms and ISO 3 and ISO 7 technology.

• Exosomes are nano-sized extracellular vesicles, ranging 30-100 nanometers in diameter, secreted from the membranes of many cells, in this case, MSCs (Mesenchymal Stem Cells). They consist of lipids, proteins, nucleic acids and are acellular. Studies have confirmed that these extracellular vesicles have beneficial effects on inflammation, autoimmunity and regeneration, and contain over 300 growth factors responsible for wound repair and tissue regeneration.

• Mesenchymal Stem Cells (MSCs) are human placenta and umbilical cord lining derived cells with self-renewing ability and can differentiate into various cell lineages. Multiple studies have reported that MSCs could elicit therapeutic effects via differentiation and/or secretion of factors such as growth factors, cytokines, and chemokines.

• Neutrophil growth factors in MSCs are a type of leukocytes, or white blood cells. They play an important role in the immune system of the body, and they are one of the first blood cells to be sent to the site of infection as they can digest and break down pathogens and other bad guys such as prions and viruses. They are the most abundant type of leukocytes / white blood cells in MSCs.
  

• Evora Biosciences      (XXX)

• √ EVOGEX is Evora’s proprietary therapeutic discovery platform that leverages engineered exosomes. The purpose of EVOGEX is to enhance key properties of exosomes and to improve the efficacy of exosome-based therapeutic approaches. Evora is developing its EVOGEX-Digest based on world-class research in copolymer gels and exosomes from CNRS and Paris University laboratories. Its lead product, EVOGEX-Digest, aims to substantially improve patient outcomes in several GI-related indications.
  

• Evox Therapeutics      (XXX)

• √ Evox Therapeutics is a platform technology company spearheading the development of exosome therapeutics for the treatment of life-threatening diseases. It is combining groundbreaking exosome technology from two renowned institutions in exosome research, Oxford University and the Karolinska Institutet. It has built a comprehensive IP portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas. In collaboration with Takeda. Evox Therapeutics and Takeda are in collaboration for their lead product in preclinical development that treats Niemann–Pick disease type C, a disorder in which a defective cholesterol transporter Niemann– Pick type C1 (NPC1) results in cholesterol accumulation inside the cell.
  

• FOx Biosystems Diagnostics      (XXX)

• √ FOx Biosystems is a Belgian company developing an integrated purification and quantification tool based on affinity-based fiber optic SPR technology that can be used for the research and diagnostics of exosomes.
  

• GBI Bio       (Contract Manufacturing)

• √ GBI Bio has deep experience in the exosome space, operating in stealth mode until recently. The company offers CDMO support for companies who are developing and commercializing exosome products. Headquartered near Fort Lauderdale, Florida, it is a fully integrated cGMP Contract Manufacturing Organization with experience across a diverse range of advanced therapies, including exosomes as well as monoclonal antibodies, recombinant proteins, vaccines, Antibody Drug Conjugates (ADCs), and other bioconjugates.

• Genflow Biosciences (Pre-Clinical Biotech)

  Genflow and EXO Biologics have initiated a 3-year scientific program, supported by a grant of 1.55 million euros. The project focuses on the development of a novel mRNA delivery system using exosomes to encapsulate and transport Genflow’s proprietary centenarian SIRT6 gene. This cutting-edge approach aims to harness the natural advantages of exosomes, such as enhanced stability, improved cellular uptake, reduced immunogenicity, minimal toxicity, natural cargo sorting and reduced off-target effects, among others. This endeavour not only demonstrates Genflow’s momentum in leading-edge research, but also holds the potential to revolutionize therapeutic interventions for Werner Syndrome, an accelerated ageing condition and holds great promised for a range of other age-related conditions.
  

• Hilltop Biosciences      (Veterinary Biotech)

• √ Located at the Mansfield BioIncubator in Massachusetts, Hilltop Bio is an innovative veterinary biotech company that develops exosome therapies to help reduce inflammation, accelerate healing, and normalize damaged tissue function in horses and companion animals. The company is leveraging its IP portfolio into a strong pipeline of off-the-shelf, room temperature biologic products. The company’s recent round of funding was led by Launchpad Venture Group.
  

• HansaBioMed Life Sciences. (Research Support)

• √ Our mission is to develop and commercialize proprietary platforms, kits, reagents and equipment for exosomes research in the Life Science market.

  HansaBioMed Life Sciences, founded in 2007, is the first company entirely focused on the research in the field of exosomes, extracellular vesicles (EVs) and nanoparticles. Today HansaBioMed collaborates with various international research groups, both Academic and Industrial, and participates in research projects aimed to implement the knowledge on the full potential of the EVs. With our expertise, gathered in over 10 years of activity, we actively work not only to improve the current technologies for EV isolation and characterization but also to investigate new fields of application of the extracellular vesicles.
  
  Our service portfolio includes scalable and automated purification of extracellular vesicles from conditioned media, biofluids or plant extracts, bulk or single EV characterization, biomarker assessment by mass spectrometry and RNA seq.
  Our catalog of products includes a broad range of purified EVs, tools for EV purification, enrichment and characterization.  Our facilities are located in Tallinn (Estonia), in the Technology park Tehnopol.
  

• Hopstem Biotechnology Co., Ltd. (Clinical Stage Biotech)

• √ Hopstem Bioengineering Co., Ltd. was founded on January 2017 in Hangzhou, by neuroscientists and stem cell biologists from Johns Hopkins University. Hopstem has established world-leading iPSCs platform of neural differentiation and cell engineering. Hopstem has developed several critical patented technologies，as well as CMC platform for iPSC-derived cell therapy products. Hopstem has iPSC reprogramming patent, GMP iPSC line with global licensing rights, iPSC-derived cell product manufacturing and quality system, and a variety of cell therapy products and pipelines, targeting CNS diseases, optical diseases and tumor. Hopstem’s first clinical product - neural progenitor cell hNPC01 targets neural injury diseases such as stroke and traumatic brain injury, has received China's IND approval and entered clinical trials. Hopstem is committed to translating the most cutting-edge technologies to provide global patients with safe, efficient and affordable cell therapy products.

• Human Forebrain Neural Progenitor Cell hNPC-01 Exosomes targeting: Autism and Alzheimer’s Disease

• Tel：0571-88197776Email：info@hopstem.com

• [2020] Exosomes derived from human induced pluripotent stem cell-derived neural progenitor cells protect neuronal function under ischemic conditions
  

• Ilias Biologics Inc      (Clinical Stage Biotech)

• √ ILIAS developed a unique platform technology EXPLOR™ that makes it possible to load specific proteins into exosomes in a controllable way. Unlike the conventional methods employing passive loading of cargoes, EXPLOR™ allows active and reversible loading of target proteins into exosomes with high efficiency. ILIAS built a robust pipeline that covers inflammatory and metabolic diseases as well as cancers. Its therapeutic exosomes showed promising efficacy profiles in non-clinical studies and ILIAS is getting ready to start a clinical trial in 2021.
  

• INOVIQ Ltd      (Diagnostics)

• √ INOVIQ Ltd (ASX:IIQ) is aggregating a set of diagnostic and exosome-based products for the earlier detection, diagnosis, prognosis and monitoring of cancer and other serious diseases. Specifically, INOVIQ’s EXO-NET® product allows for “fast, accurate, and efficient capture and isolation of exosomes from any liquid biopsy sample.” The technology is scalable and compatible with existing automated testing systems, making it well-suited for high volume clinical lab applications.
  

• Innovaprep.    (Isolation and Concentration of Biologics)

• Microbiology processes are complex, especially the preanalytical steps.

• This is the stage in sample processing that impacts your results the most and requires the most labor, skill, and time. If your lab is still using outdated sample prep methods, it is time to get up to speed.

• Dreaming of faster and easier workflows, better detection efficiency, and reproducible results? Our tools allow you to bypass time-consuming sample preparation steps while achieving the highest concentration factors possible for same-shift results.

• Acquired Clara Biotech, Oct 2023
  

• Invitrx Inc      (XXX)

• √  Product Link: Reluma

• Invitrx’s EX-MSC is an exosome allograft derived from Wharton’s Jelly MSCs and is sourced from a proprietary blend of cells developed for growth and repair. Exosomes and other Extracellular Vesicles (EVs) are isolated from their parent cells and concentrated to produce the Exosomal Product.
  

• Jupiter BioLife      (P4$ / Biotech)

• Jupiter BioLife is a biotech company that specializes in the development of exosomes for therapeutic purposes. Our trademarked exosomes, Immunosomes, Dermasomes, Hairsomes, Chondrosomes, and Periosomes, are specifically designed to target immune system health, skin and hair health, joint health, and periodontal health, respectively. All of our exosomes are loaded with beneficial growth factors and cytokines that are designed to maximize health and wellness. Jupiter BioLife is committed to helping people live healthier, more fulfilling lives through the use of exosomes.

CHONDROSOMES 1CC $570.00 – $3,800.00

DERMASOMES 1CC $249.00 – $1,950.00

HAIRSOMES 1CC $385.00 – $2,900.00

IMMUNOSOMES 1CC $570.00 – $3,800.00

PERIOSOMES 0.5CC $249.00 – $1,950.00

• Kimera Labs      (P4$ / Clinical Stage Biotech) (Placental MSC)

• √  Kimera Labs is a regenerative medicine focused biotechnology company specializing in exosome manufacturing. Its XoGlo™ product is an isolated, xeno-free, chemically defined, cell-free placental MSC derived exosome re-suspended in 0.9% normal saline.  According to the company, this cosmetic product contains a multitude of growth factors, which are involved in skin repair, beautification and regeneration.  The company also manufactures sterile, pharmaceutical-grade mesenchymal stem cell exosomes for future IRB-approved clinical research.

• Kimera owns a sophisticated lab capable of characterizing the complete envelope of exosome characteristics. This ability is available as a contract service.

• Kimera:  | Placental Mesenchymal Stem Cell Exosomes | Frozen | Topical / Injectable

  • VIVE 1 ml 5B Exos $135.00

  • Lux 1 ml Placental Mesenchymal Stem Cell Exosomes

  • Lux+ 5 ml. Placental Mesenchymal Stem Cell Exosomes
    

• Lonza      (Public (LONN)) (Pharmaceuticals) 

• HansaBioMed Life Sciences

• Exosomics

• √  Lonza Group is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia.

• In May 2017, Lonza acquired HansaBioMed Life Sciences based in Tallinn, Estonia, a start-up company dedicated to the research and development, manufacturing, and distribution of products for the exosomes research market. Now under the Lonza brand, HansaBioMed Life Sciences Ltd (HBM-LS) develops products in the field of exosome sciences and offers an advanced portfolio of products and services for EV research. (Lonza is also the leading and strategic investor in Exosomics Group, another exosome company.)

• MesenBio. (Preclinical Biotech) (Rheumatoid arthritis)

• Mesenbio is a preclinical stage biopharmaceutical company spinout from the University of York. Our Cell Line Extracellular Vesicle Release (CLEVR) platform enables us to pursue a varied therapeutic pipeline by addressing the most prevalent bottleneck in extracellular vesicle therapeutics: consistency.

  We leverage our platform to produce a consistent, endless supply of therapeutically exciting extracellular vesicles. Our aim is to transform medicine by unlocking extracellular vesicles as a novel treatment modality.

  We have shown that our cells produce naturally bioactive extracellular vesicles with combined anti-inflammatory and pro-regenerative potential, and are pursuing an internal pipeline to address musculoskeletal disease that takes advantage of this unique capability.

  CLEVR can also enable discovery and development of interventions for other indications, and we are happy to discuss potential synergies with new partners.
  

• MesoPeptice      (P4$ / Biotech) 

• MesoPeptice:  | Umbilical Cord Mesenchymal Stem Cell Exosomes | Frozen | Topical / Injectable

  • Exosome 20 1 ml 20B Exos $??.00

• √  The superiority of umbilical cord driven exosome 20, compared to the other exosome based based products in the market?

• MDimune Inc      (XXX)

• √  MDimune is a cell-derived vesicle (CDVs)-based therapeutics company that has developed a BioDrone® platform technology, which is a novel technology that uses cell-derived vesicles to achieve highly target-specific drug delivery. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. MDimune’s current programs are focused on cancer, COPD and other rare diseases.
  

• Microgentas      (XXX)

• √  Headquartered in Seoul, South Korea, Microgentas focuses on integrated exosome isolation and miRNA extraction. The company provides solutions to sample preparation challenges with its core technologies, offering faster, cost-effective, scalable, user-friendly exosome isolation kits: ExoCAS™, ExoPAS™, ExoFilter™, and exosomal microRNA extraction kits, miRQuick™. Microgentas is also developing EV research related to exosome-based biomarkers for diagnosing and monitoring breast cancer, collaborating with Korea University Anam Hospital.
  

• NanoView Biosciences (Aquired by Unchained Labs)

• NanoView Biosciences was founded on a technology platform that uniquely identifies and characterizes exosomes. Its ExoView™ platform provides the ability to measure up to 4 markers on a single extracellular vesicle, with single binding event sensitivities.
  

• NanoSomiX      (XXX)

• √  Unlocking the Mysteries of the Brain

• The brain is the most complex and least understood organ in the body. NanoSomiX, Inc. is at the forefront in establishing an entirely new class of non-invasive testing to address the need for improved brain analytic tools for research and clinical applications using Brain Derived Exosomes (BDE). We are interested in working collaboratively with clinicians and researchers to use our blood-based assay technology to further biomarker exploration in neurologic disorders.

• Exosomes are extremely small, membrane-bound vesicles produced by cells throughout the body. NanoSomiX is specifically focused on BDEs produced by various brain cell populations. A characteristic of BDEs is that they carry brain-produced biomarkers that relate to brain function and are released into the blood stream. As a result, BDE biomarker assessment can be done using a simple blood draw and can provide information on the status of tissue in the brain.

• Our laboratory is working with both academic researchers and commercial companies to support ongoing research into biomarkers associated with various neurologic disorders and neurotrauma. Much of our contract work involves studies to confirm the detection of BDE biomarkers of interest, and to design protocols for diagnostic and monitoring applications. Working within a CLIA laboratory environment, we can provide a blood-based assay that is repeatable, cost effective and fits easily into a routine diagnostic or research environment.

• Our proprietary exosome isolation and analysis technologies are covered by a series of recently granted patents, with several additional patent applications in process to cover various aspects of BDE processing and marker application. Using BDEs to explore clinical applications in neurologic disorders is supported by several peer-reviewed publications.
  

• Novaxomx      (XXX)

• √  Novaxomx is a joint venture of curasan AG and Xlife Sciences that is researching and developing exosome based therapies to support musculoskeletal recovery.
  

• NurExone Biologic      (Clinical Stage Biotech)  (TSXV: NRX)

• √  NurExone Biologic Ltd is developing a novel biological extracellular vesicles-based technology drug platform to treat damage of the Central Nerve System (CNS). Its focus is on the regenerative potential of cell-free MSC-derived EVs.

  • ORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies.

    NurExone’s Intellectual property portfolio describes the ExoTherapy platform’s comprehensive technology and processes for the production of nanodrugs including large scale production of exosomes, loading of active molecules and the composition of the exosomes themselves. The loading technology was presented to the public in the press release of February 12, 2024. Today the Company is highlighting its innovative bioreactor and biological processes for:

    1. High yield repeatable production of exosomes

    2. Production of natural and potent exosomes (not synthetically engineered)

• Oasis Diagnostics      (Diagnostics)

• √  As a pioneer in the area of salivary diagnostics, Oasis Diagnostics® Corporation provides tools for the simple and immediate isolation of exosomes, cell free DNA, cell free RNA [miRNA, mRNA] from saliva specimens. As part of its long term goals in this area the Company is involved in the characterization of salivary exosomes, particularly looking at the nature of salivary exosomes, what they are, what role they play, how they can be employed as diagnostics to pinpoint specific diseases and whether there are unique differences between exosomes from normal, healthy individuals and those with targeted diseases.
  

• OmniSpirant      (Inhalation Therapies) (Respiratory Diseases)

• √  OmniSpirant has a patent pending platform technology based on inhaled bioengineered stem cell exosomes, which are capable of efficient intracellular delivery of a variety of therapeutic cargoes to effectively treat respiratory diseases. Its engineered stem cell exosomes will initially be used to develop a first-in-class regenerative gene therapy for Cystic Fibrosis. The proprietary mucus penetrating exosomes have similar transformative potential for treating many other respiratory diseases.
  

• Omni-Stem

• Omni-Stem is a Colombia-based biotech company founded in 2020 that specializes in regenerative medicine using advanced stem cell and exosome therapies. We offer treatments for various conditions, including autoimmune disorders, degenerative diseases, and orthopedic injuries. Our state-of-the-art clinic and protocols ensure the highest standards of patient care.

  We focus on direct patient care and are committed to advancing regenerative medicine through global scientific collaborations.
  

• ONI (Super-Resolution Microscopes)

• We believe that understanding science at a molecular level will fundamentally allow you to unlock new discoveries, so we created our flagship product, The Nanoimager. We built the world's first desktop compatible compact super-resolution microscope, but we did it our way. Our teams have a restless enthusiasm to bring technologies like super-resolution to a new community of researchers and we continue working until barriers of accessibility and affordability are addressed. Our mission is to ensure research and collaboration tools are available to those willing to ask why or how things are the way they are and answer questions never asked before.

• Omni-Stem is a Colombia-based biotech company founded in 2020 that specializes in regenerative medicine using advanced stem cell and exosome therapies. We offer treatments for various conditions, including autoimmune disorders, degenerative diseases, and orthopedic injuries. Our state-of-the-art clinic and protocols ensure the highest standards of patient care.

  We focus on direct patient care and are committed to advancing regenerative medicine through global scientific collaborations.
  

• Organicell      (XXX)

• √  Organicell™ describes itself as a fully integrated Exosome Therapeutics Company. Its Zofin™ product contains approximately 400 billion exosomes per milliliter quantified in every batch by Nanosight technology. Exosomes are nanovesicles that contain protein and microRNA that can be transferred to other cells to support tissue repair and homeostasis.
  

• Primoris Therapeutics      (XXX)

• √  Primoris Therapeutics is an umbilical cord blood mesenchymal stem cell-released exosome (ExoPlusTM)-based biomedicine development company and headquartered in Republic of Korea. ExoPlusTM is a functionally reinforced-exosome with both enhanced inflammation inhibition and tissue regeneration effects through its own proprietary technologies. ExoPlusTM has been manufactured at GMP facilities of Kangstem Biotech for clinical and commercial use. Preclinical studies have been completed and Phase I/II clinical trials for burn treatment will be conducted in late 2023.
  

• Regenerelle      (XXX)

• √  Regenerell is aggregating the world’s largest supply of high quality exosomes. Since coming to the market, the company has sold many trillions of Exosomes. It currently has 2,850 quintrillion exosomes in cryo-storage at its NY State Licensed tissue bank and is producing in excess of 750 trillion exosomes derived from umbilical cord Wharton’s jelly stem cells.
  

• Regen Suppliers      (XXX)

• √  Based in Scottsdale, Arizona, Regen Suppliers announced its exosome industry involvement with a January 16, 2020, announcement stating that the company offers ReBella and ReBellaXO, umbilical stem cell and exosome products used for regenerative aesthetic procedures involving hair, facial and sexual rejuvenation. According to the company, ReBellaXO is an MSC Derived Exosome Biologic that is a “minimally manipulated allograft derived from full term, post c-section umbilical cord tissue and Wharton’s Jelly.”

• Are Exosome Product Counts a Fallacy? How Exosome Companies Manipulate Their Results

• Potent MSC Derived Exosome Supplier of ReBella
  

• ReNeuron      (XXX)

• √ ReNeuron is a UK-based stem cell company developing therapies for unmet medical needs. ReNeuron has developed a technological process enabling it to produce exosomes from a cell line, such as its proprietary CTX neural stem cell line under different culture conditions, which can in turn be harvested at a commercially relevant scale.
  

• Rion      (Clinical Stage Biotech)      (Platelets)

• Rion is an exosome company based out of Rochester, Minnesota. The company was incorporated since 2017 and is now advancing various R&D and clinical programs. Rion has created a Purified Exosome ProductTM (PEPTM), an biologic platform that leverages the therapeutic power of exosomes as a shelf-stable, allogeneic (donor-derived) product. PEP is Rion’s core technology that has the potential to support tissue regeneration across a diverse range of conditions, including wound healing, cardiovascular disease, knee osteoarthritis, and women’s health indications.

• Rion has 3 active clinical trials, which include Wound Healing (NCT04664738), Acute Myocardial Infarction (NCT04327635), and Crohn’s Fistulizing Disease (IND 018436).

  • RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers

• RION harnesses the unique regenerative properties of platelets, an ideal source of regenerative exosomes, due to their natural role in healing and regeneration.

• Unlike other sources, platelet-derived exosomes are inherently designed to promote tissue repair, making them a superior choice for therapeutic applications.

• Platelets are natural, sustainable, and a cost-effective source of regenerative exosomes.
  

• RoosterBio Inc.      (P4$ / Clinical Development Support)

  (Umbilical | Bone Marrow | Adipose)

• √ At RoosterBio, we are experts in radically simplifying the use of adult human mesenchymal stem/stromal cells (hMSCs) to propel the commercialization of therapeutic technologies. By enabling living cells to become more affordable at the lowest cost per million cells with industry leading quality, we make MSCs easier to access and much simpler to incorporate into product development efforts, leading to rapid acceleration in products coming to market that incorporate these technologies.

• In August 2017, RoosterBio Inc and Exopharm Pty Ltd announce an agreement under which they will work together on a Stem Cell Exomere Program, aimed at bringing high-grade therapeutic extracellular vesicles/exosomes derived from adult stem cells into clinical practice. According to the companies, they are working together to develop and implement a standardized, scalable, commercially-viable biomanufacturing process utilizing Exopharm’s Exomere technology in order to enable rapid clinical translation with a cGMP-compliant Exomere product into regenerative medicine (RM) applications.

• 1 – 4 vials / $975 per vial

• 5 – 9 vials / $925 per vial

• 10+ vials / $875 per vial
  

• ShiftBio      (XXX)

• SHIFBIO INC., based in Korea, is pioneering immunoregenerative Cell-Free Nanotherapy Platform Technologies using natural nanovesicles (exosomes) to create a new class of medicines. Their technologies empower nanovesicles by maximizing therapeutic protein expression, loading macromolecules, or enabling in vivo cell manipulation to tackle intractable and rare diseases. The lead program is based on Maxisome platform technology, which maximizes the expression of therapeutic proteins on the surface of nanovesicles for enhanced efficacy. The second platform technology, InProDel, enables intracellular delivery of previously “undruggable” macromolecules in a free-form state and efficiently delivers them to target cells. Lastly, its Fusosome platform technology enables a selective fusion of nanovesicles with target cell membranes and facilitates “in vivo manipulation” of the recipient cells. These technologies have the potential to revolutionize regenerative medicine.

• DOUGLAS J. SPIEL, M.D. (Clinical Practice) (Pain)

  Douglas Spiel has extensive knowledge in both treating patients and teaching doctors with the Kimera product. He is the author of the chapter on exosomes for the regenerative medicine textbook published by the American Society of interventional Pain Physicians. Prior to the pandemic, Dr. Spiel was universally seen as a pioneer and thought leader in this space having personally treated nearly one thousand patients with Kimera exosomes and having taught thousands of physicians worldwide. His diverse knowledge across numerous clinical fields combined with his hands-on treatment of so many patients affords him a very unique perspective on mechanisms of action, safety and efficacy. During his tenure as the Chief Medical Officer of Kimera Labs, his protocols served as the yardstick that numerous others emulated and followed. A consummate professional, he continuously fielded all calls and inquiries and served as an onsite clinical teaching lab for physicians worldwide desiring to learn both his techniques and protocols.

• Dr. Spiel maintains two clinics, one in New Jersey focused on Pain Management and one in Anguilla, specializing in the utilization of exosomes for a number of indications.

• Email: frontdesk@stopfathertime.com. • Phone: 844-882-4300

• Stemcell Medicine Ltd.      (XXX)

• Announced January 2018, Stem Cell Medicine Ltd. (SCM) has licensed an innovative exosome-based technology for the treatment of neurodegenerative and neuropsychiatric indications, specifically, autism spectrum disorder (ASD). The treatment is based on vesicles, exosomes, derived from adult stem cells (MSC-exo) that are administered intranasally. The technology was developed by Professor Dani Offen, Sackler School of Medicine, Sagol School of Neurosciences Tel Aviv University and was licensed from Ramot, the Business Engagement Center at Tel Aviv University.

• Supreme Rejuvenation (P4$)

• Supreme Rejuvenation is leading the way in the science and technology industry, using groundbreaking innovation to revolutionize healthcare. Our product range is carefully crafted to not only enhance physical and mental performance but also to boost energy levels and overall vitality, delivering tangible benefits for patients and practitioners alike.

  Our overarching goal is to cultivate a culture of bio-wellness, one that seeks harmony within the mind, body, and cellular processes. Through comprehensive education, we strive to ignite a passion for optimizing bodily functions, improving health, and unlocking an individual’s fullest potential.

  At the heart of our offerings lies our MSC exosome product line. These exceptional exosomes are meticulously designed to elevate the body’s performance, enabling individuals to reach their health and life goals with unprecedented efficacy.

  Supreme Rejuvenation firmly believes that balance and vitality are the cornerstones of a fulfilling life. We are wholly dedicated to providing the tools and knowledge necessary for individuals to embark on transformative journeys toward better health and well-being.

  Our commitment to innovation and excellence positions us as a valuable partner for healthcare providers and institutions. Join us in this journey towards a healthier and more vibrant future.

  Pharmaceutical-Grade Mesenchymal Exosome Products, Crafted to the Highest Current Good Manufacturing Practice (cGMP) Standards.

  • Human umbilical cord exosomes; 20 Billion

  • Human umbilical cord exosomes; 40 Billion

  • Human umbilical cord exosomes; 100 Billion

  • Stem cell exosome gel; 100 Billion

  • Stem cell exosome gel; 200 Billion

  • 11861 S Sam Houston Parkway, Suite A Houston, TX 7703

  • info@supremerejuvenation.com

  • 713-309-6771

  • Instagram Tiktok
    

• TAVEC Pharmaceuticals      (XXX)

• Tavec is developing the next-generation of potent anti-cancer gene therapies using the power of injectable, miRNA loaded exosomes. It has demonstrated an ability to deliver high levels of specific miRNA, including widely known cancer disruptive targets such as miR195, directly to cancer cells. Using in vivo models,  its miRNA-loaded exosomes inhibit cancer growth and prolong lifespan. The company is focused on exploiting a cancer cells natural pre-disposition to taking up large quantities of certain types of exosomes to insert microRNAs that will disrupt the cancer growth instruction set.
  

• The Cell-Factory BVBA (Esperite)   See Parant Company: Esperite

• √ The Cell Factory, is a platform-based biotech company focused on innovative products development, clinical translation and commercialization. It is developing extracellular vesicles (EVs) and exosomes, in particular allogenic “off-the-shelf” MSC-derived EVs and exosomes to used as inhibitors of acute and chronic inflammation and immunosuppressants in the treatment of unmet medical needs. Its target diseases are Crohn’s disease, drug-resistant epilepsy, and others. It fully owns a patent family on broad applications of MSC-derived EVs and exosomes in treatment of various inflammatory diseases.
  

• TheraXyte BioScience      (XXX)

• √ TheraXyte BioScience is a biotech company focusing on extracellular vesicle (EV)-mediated drug delivery and EV-based novel therapeutics.  The company has developed an EV-based drug delivery platform (TAXY™) which could enable the mass production of modifiable EVs at GMP manufacturing level. It is being designed to facilitate payload packaging so that it can assist in targeting organs/cells of interest where payload drug molecules and active biological molecules could be released as therapeutics.

• Unchained Labs      (Laboratory Equipment)

• √ Laboratory equipment focused on biologics
  

• Unicyte AG      (XXX)

• Headquartered in Oberdorf, Switzerland, Unicyte AG evolved from a fifteen year research collaboration with Prof Giovanni Camussi, a leading expert on extracellular vesicles and stem cells from the University of Turin and Fresenius Medical Care KGaA, the world’s largest provider of products and services for individuals with renal diseases. As a pioneer in liver stem cells and nano-extracellular vesicles, the company is dedicated to improving the lives of patients with kidney or liver disease, diabetes, and cancer. Unicyte was founded in 2015 as an independent affiliate of Fresenius Medical Care and is headquartered in Oberdorf NW, Switzerland.

• United Therapeutics

• United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them!

  Develop scalable cell culture and exosome purification processes to improve production of regenerative medicine products.

  Key Accountabilities / Responsibilities:

  • Lead efforts in upstream bioprocess development, with particular focus on the efficient expansion of adherent and non-adherent cells (e.g. stem cells, adult primary cells) in cell culture bioreactors

  • Conduct insightful studies to improve the yield (biogenesis) and/or potency of therapeutically-relevantexosomes
    

• US EXOSOMES      (P4$ / XXX)

• Very little information is provided on this site.

• (1ml ) Vial $2,000     20 Billion Exosomes

  (2ml ) Vial $3,000    40 Billion Exosomes

• (5ml ) Vial $5,000     100 Billion Exosomes

  (15ml) Topical Gel $2,000     100 Billion Exosomes

  (30ml) Topical Gel $3,000     200 Billion Exosomes
  

• Versatope      (XXX)

• √ Headquartered in Lowell, Massachusetts, Versatope is using recombinant extracellular transport vesicles to deliver vaccines. Specifically, it is leveraging Recombinant Extracellular Transport Vesicles (RET-Vs) to deliver payloads that can modify a target cell’s activity.

• Vesicure Therapeutics (Pre-Clinical Biotech)

• √ Vesicure extended the feasibility of this exosome-siRNA technology in targeting KRAS mutation in a CDX (Cell line-derived xenograft) mouse model (BioRxiv: doi: https://doi.org/10.1101/2024.01.17.576015). The data revealed that intravenously (iv) injected exosomes were enriched in tumors. These 'KRAS siRNA carriers' exhibited excellent tumor retention and growth inhibition without significant toxicity to mice. This advancement marks progress in developing exosomes for extrahepatic siRNA drug delivery for targeting previously deemed undruggable targets to address unmet therapeutic needs.

  • vesicure@vesicure.com 

  • https://vesicure.com/

  • [2023] Harnessing extracellular vesicles for efficient siRNA delivery in vitro and in vivo

  • [2024] Therapeutic targeting of KRAS mutation-driven tumorigenesis by extracellular vesicles loaded with small interfering RNA
    

• VivaZome Therapeutics Pty Ltd      (XXX)

• √ VivaZome Therapeutics Pty Ltd is a privately-held Australian biotech company, based in Melbourne, Victoria. It was formed to develop and commercialise exosome-based therapies, with a focus on treatments for debilitating and/or life-threatening disorders which are not adequately managed by current therapies.

• Waisman Biomanufacturing (Contract Development and Manufacturing Organization (CDMO))

• “Waisman Biomanufacturing occupies a unique and critically important niche in the biologics CDMO landscape,” said Tim Kelly, Chief Executive Officer of RoosterBio. “For over 20 years, Waisman has built a track record of success in clinical manufacturing of biologics for a broad range of clients in emerging biopharma and institutional settings, where much of the innovation in advanced therapy development resides. I am very excited to partner with Waisman to provide scalable manufacturing solutions to our clients and deliver highly impactful advanced therapies to patients everywhere.”

• Waisman Biomanufacturing, a leading contract development and manufacturing organization (CDMO) which is strategically part of the University of Wisconsin Madison, announced today a strategic partnership with RoosterBio, Inc., a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.  

• Strategically part of the University of Wisconsin-Madison, WB maintains industry-standard facilities, equipment, and quality systems with a scientific staff that provide a highly flexible and collaborative project management approach. WB has a proven track record for producing high-quality clinical trial material for both large and small biotech companies, universities, and federal agencies for regulatory filings in the US and other global markets.

• Waisman Biomanufacturing has manufactured hundreds of clinical grade products since inception in 2001 and has earned a reputation as a strategic partner for cost effective and timely delivery. We strive to meet these high standards with each manufacturing campaign or development program.
  

• Wellbeing International Foundation        (XXX)

• √ Wellbeing International Foundation is a medical services company that can call upon over 25 years of scientific and medical research and expertise in the fields of stem cell derived therapies and regenerative medicine.

• We advise on two types of medical service: cell-free therapy based on the use of extracellular vesicle secretions, and dendritic cell treatment as an alternative, or supplement to, conventional cancer therapy.
  

• XOStem Inc      (XXX)

• √ XOStem, Inc. was registered as a company in Delaware on May 9, 2018. While there is limited information available about the company, XOStem appears to be primarily focused on Type One Diabetes. 
  

• XO Scientific      (P4$ / XXX)       (Umbilical Cord MSCs)
  

  • Umbilical Cord MSC Exosomes $2250
    

• Yuvan Research      (Pre-Clinical Biotech)      

• Custom

• √ Lead Product: E5

• ZenBio      (XXX)       (Adipose Adult Stem Cells) and (Placental (MSC)

• √ Custom exosome isolation